|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
Address1 | 601 PENNSYLVANIA AVENUE, NW |
Address2 | SUITE 700 |
City | WASHINGTON, DC |
State | DC |
Zip Code | 20004 |
Country | USA |
3. Principal place of business (if different than line 2)
City | |
State | |
Zip Code | |
Country | |
|
5. Senate ID# 89177-12
|
||||||||
|
6. House ID# 366750000
|
TYPE OF REPORT | 8. Year | 2008 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
10. Check if this is a Termination Report | Termination Date | |
11. No Lobbying Issue Activity |
INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
---|---|---|---|---|---|---|---|---|---|
12. Lobbying | 13. Organizations | ||||||||
INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
Signature | Digitally Signed By: Peter Begans, Vice President, Federal Government Affairs |
Date | 04/21/2008 |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
Health Information Technology, Electronic Prescribing, Genetic Nondiscrimination, Inappropriate use of Human Growth Hormone, Contract Dislcosure Regulations, Comparative Effectiveness, 340B Program, Confidentiality of Health Information, Generic Drugs, Generic Biologics, Internet Pharmacies, Off-Label Use of Prescription Drugs.
HR 493 and S 358 - Genetic Information Nondiscrimination Act of 2007; Title I
HR 971 and S 885 - Community Pharmacy Fairness Act of 2007; all aspects
HR 1432 and S. 316 - Preserve Access to Affordable Generics Act; all aspects
HR 1474 - Fair and Speedy Treatment (FAST) of Medicare Prescription Drug Claims Act of 2007; all aspects
HR 1956 - Patient Protection and Innovative Biologic Medicines Act of 2007; all aspects
HR 2567 and S 870 - Medicare Home Infusion Therapy Consolidated Coverage Act of 2007; all aspects
HR 2606 and S 1376 - 340B Program Improvement and Integrity Act of 2007; all aspects
HR 2914 - Medicare IVIG Access Act of 2007; all aspects
HR 2970 - Pharmacy Benefit Manager Transparency Act of 2007; all aspects
HR 3140 - Saving Our Community Pharmacies Act of 2007; all aspects
HR 3090 - Patient and Pharmacy Protection Act of 2007; all aspects
HR 3193 - Access to Community Pharmacy Preservation Act of 2007; all aspects
HR 3800 - Promoting Health Information Technology Act; all aspects
HR 3932 - Medicare Prescription Drug Savings and Choice Act of 2007; all aspects
HR 4296 and S 2408 - Medicare Electronic Medication and Safety Protection (E-MEDS) Act of 2007; all aspects
H.R. 5629 - Pathway for Biosimilars Act; all aspects
S 28 - Generics First Act of 2007; all aspects
S 242 - Pharmaceutical Market Access and Drug Safety Act of 2007; all aspects
S 251 - Pharmaceutical Market Access Act of 2007; all aspects
S 273 - Prescription Drug and Health Improvement Act of 2007; all aspects
S 596 - Safe Internet Pharmacy Act of 2007; section 511(c); all aspects
S 976 - Genomics and Personalized Medicine Act of 2007; all aspects
S 980 - Online Pharmacy Consumer Protection Act of 2007; all aspects
S 1408 - Health Information Technology Act of 2007; all aspects
S 1507 - Access to Medicare Data Act of 2007; all aspects
S 1693 - Wired for Health Care Quality Act; all aspects
S 1695 - Biologics Price Competition and Innovation Act of 2007; all aspects
S. 1814 - Health Information Privacy and Security Act; all aspects
S 1954 - Pharmacy Access Improvement (PhAIm) Act of 2007; all aspects
S 2161 - Community Pharmacy Fairness Act of 2007; all aspects
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Agency for Health Care Policy & Research, Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Executive Office of the President (EOP), Federal Trade Commission (FTC), Food & Drug Administration (FDA), Health & Human Services - Dept of (HHS), Labor - Dept of (DOL), Medicare Payment Advisory Commission (MedPAC), Food & Drug Administration (FDA)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Peter |
Begans |
|
|
|
Bill |
Head |
|
|
|
Hallie |
Lewis |
|
|
|
Heather |
Stewart |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
Medicare Part D, Prompt Payment to Pharamcies, Antitrust Exemption for Pharmacists, IVIG Payments, Tracking or Pedigree of Prescription Drugs, Reimportation of Prescription Drugs, Medicare Demonstration Project for Durable Medical Equipment.
HR 2567 and S 870 - Medicare Home Infusion Therapy Consolidated Coverage Act of 2007; all aspects
HR 2606 and S 1376 - 340B Program Improvement and Integrity Act of 2007; all aspects
HR 2914 - Medicare IVIG Access Act of 2007; all aspects
HR 3700 Fair Medicaid Drug Payment Act of 2007; all aspects
HR 4296 and S 2408 - Medicare Electronic Medication and Safety Protection (E-MEDS) Act of 2007; all aspects
S 242 - Pharmaceutical Market Access and Drug Safety Act of 2007; all aspects
S 251 Pharmaceutical Market Access Act of 2007; all aspects
S 273 Prescription Drug and Health Improvement Act of 2007; all aspects
S 1507 Access to Medicare Data Act of 2007; all aspects
S 2219 Medicare Prescription Drug Savings and Choice Act of 2007; all aspects
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Centers For Medicare and Medicaid Services (CMS), Health & Human Services - Dept of (HHS), Executive Office of the President (EOP)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Peter |
Begans |
|
|
|
Bill |
Head |
|
|
|
Hallie |
Lewis |
|
|
|
Heather |
Stewart |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code PHA
16. Specific lobbying issues
Electronic Prescribing, Pharmacy Payments, Pharmacy Antitrust Exemption, Internet Pharmacies.
HR 971 and S 885 - Community Pharmacy Fairness Act of 2007; all aspects
HR 1474 - Fair and Speedy Treatment (FAST) of Medicare Prescription Drug Claims Act of 2007; all aspects
HR 2970 - Pharmacy Benefit Manager Transparency Act of 2007; all aspects
HR 3140 - Saving Our Community Pharmacies Act of 2007; all aspects
HR 3090 - Patient and Pharmacy Protection Act of 2007; all aspects
HR 3193 Access to Community Pharmacy Preservation Act of 2007; all aspects
S 242 - Pharmaceutical Market Access and Drug Safety Act of 2007; all aspects
S 251 - Pharmaceutical Market Access Act of 2007; all aspects
S 596 - Safe Internet Pharmacy Act of 2007; section 511(c)
S 980 - Online Pharmacy Consumer Protection Act of 2007; all aspects
S 1954 - Pharmacy Access Improvement (PhAIm) Act of 2007; all aspects
S 2161 - Community Pharmacy Fairness Act of 2007; all aspects
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Centers For Medicare and Medicaid Services (CMS), Drug Enforcement Administration (DEA), Executive Office of the President (EOP), Health & Human Services - Dept of (HHS), Justice - Dept of (DOJ)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Peter |
Begans |
|
|
|
Bill |
Head |
|
|
|
Hallie |
Lewis |
|
|
|
Heather |
Stewart |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
Address | |
||||||
City | |
State | |
Zip Code | |
Country | |
21. Client new principal place of business (if different than line 20)
City | |
State | |
Zip Code | |
Country | |
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
1 |
|
5 |
|
||||||
2 |
|
6 |
|
||||||
3 |
|
7 |
|
||||||
4 |
|
8 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
1 | 3 | 5 |
2 | 4 | 6 |
FOREIGN ENTITIES
27. Add the following foreign entities:
Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% |
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
1 | 5 | 9 |
2 | 6 | 10 |
3 | 7 | 11 |
4 | 8 | 12 |